Your browser doesn't support javascript.
Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis.
Tallantyre, Emma C; Scurr, Martin J; Vickaryous, Nicola; Richards, Aidan; Anderson, Valerie; Baker, David; Chance, Randy; Evangelou, Nikos; George, Katila; Giovannoni, Gavin; Harding, Katharine E; Hibbert, Aimee; Ingram, Gillian; Jolles, Stephen; Jones, Meleri; Kang, Angray S; Loveless, Samantha; Moat, Stuart J; Robertson, Neil P; Rios, Francesca; Schmierer, Klaus; Willis, Mark; Godkin, Andrew; Dobson, Ruth.
  • Tallantyre EC; Division of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, United Kingdom; Department of Neurology, University Hospital of Wales, Cardiff, United Kingdom.
  • Scurr MJ; Division of Infection and Immunity, School of Medicine, Cardiff University, United Kingdom; ImmunoServ Ltd, Cardiff CF15 7AB, United Kingdom.
  • Vickaryous N; Preventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University London, Charterhouse Square, EC1M 6BQ, United Kingdom.
  • Richards A; Division of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, United Kingdom.
  • Anderson V; Division of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, United Kingdom.
  • Baker D; Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, United Kingdom.
  • Chance R; Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, United Kingdom; Centre for Oral Immunobiology and Regenerative Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, United Kingdom.
  • Evangelou N; Department of Clinical Neurology, University of Nottingham, United Kingdom.
  • George K; Preventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University London, Charterhouse Square, EC1M 6BQ, United Kingdom.
  • Giovannoni G; Preventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University London, Charterhouse Square, EC1M 6BQ, United Kingdom; Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, United Kingdom; Department of Neurology, Barts He
  • Harding KE; Department of Neurology, Royal Gwent Hospital, Newport, United Kingdom.
  • Hibbert A; Department of Clinical Neurology, University of Nottingham, United Kingdom.
  • Ingram G; Department of Neurology, Morriston Hospital, Swansea, United Kingdom.
  • Jolles S; Division of Infection and Immunity, School of Medicine, Cardiff University, United Kingdom; Immunodeficiency Centre for Wales, University Hospital of Wales, Cardiff, United Kingdom.
  • Jones M; Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, United Kingdom.
  • Kang AS; Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, United Kingdom; Centre for Oral Immunobiology and Regenerative Medicine, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, United Kingdom.
  • Loveless S; Division of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, United Kingdom.
  • Moat SJ; Wales Newborn Screening Laboratory, Department of Medical Biochemistry, Immunology and Toxicology, University Hospital of Wales, Cardiff, United Kingdom; School of Medicine, Cardiff University, United Kingdom.
  • Robertson NP; Division of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, United Kingdom; Department of Neurology, University Hospital of Wales, Cardiff, United Kingdom.
  • Rios F; Preventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University London, Charterhouse Square, EC1M 6BQ, United Kingdom.
  • Schmierer K; Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, United Kingdom; Department of Neurology, Barts Health NHS Trust, London, United Kingdom.
  • Willis M; Department of Neurology, University Hospital of Wales, Cardiff, United Kingdom.
  • Godkin A; Division of Infection and Immunity, School of Medicine, Cardiff University, United Kingdom; ImmunoServ Ltd, Cardiff CF15 7AB, United Kingdom.
  • Dobson R; Preventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University London, Charterhouse Square, EC1M 6BQ, United Kingdom; Department of Neurology, Barts Health NHS Trust, London, United Kingdom. Electronic address: Ruth.dobson@qmul.ac.uk.
Mult Scler Relat Disord ; 64: 103937, 2022 Aug.
Article in English | MEDLINE | ID: covidwho-1946098
ABSTRACT

BACKGROUND:

People with MS treated with anti-CD20 therapies and fingolimod often have attenuated responses to initial COVID-19 vaccination. However, uncertainties remain about the benefit of a 3rd (booster) COVID-19 vaccine in this group.

METHODS:

PwMS without a detectable IgG response following COVID-19 vaccines 1&2 were invited to participate. Participants provided a dried blood spot +/- venous blood sample 2-12 weeks following COVID-19 vaccine 3. Humoral and T cell responses to SARS-CoV-2 spike protein and nucleocapsid antigen were measured.

RESULTS:

Of 81 participants, 79 provided a dried blood spot sample, of whom 38 also provided a whole blood sample; 2 provided only whole blood. Anti-SARS-CoV-2-spike IgG seroconversion post-COVID-19 vaccine 3 occurred in 26/79 (33%) participants; 26/40 (65%) had positive T-cell responses. Overall, 31/40 (78%) demonstrated either humoral or cellular immune response post-COVID-19 vaccine 3. There was no association between laboratory evidence of prior COVID-19 and seroconversion following vaccine 3.

CONCLUSIONS:

Approximately one third of pwMS who were seronegative after initial COVID-19 vaccination seroconverted after booster (third) vaccination, supporting the use of boosters in this group. Almost 8 out of 10 had a measurable immune response following 3rd COVID-19 vaccine.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Multiple Sclerosis Topics: Long Covid / Vaccines Limits: Humans Language: English Journal: Mult Scler Relat Disord Year: 2022 Document Type: Article Affiliation country: J.msard.2022.103937

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Multiple Sclerosis Topics: Long Covid / Vaccines Limits: Humans Language: English Journal: Mult Scler Relat Disord Year: 2022 Document Type: Article Affiliation country: J.msard.2022.103937